Vaxart Inc., a privately held clinical-stage biotechnology company that creates oral recombinant vaccines in the form of tablets instead of injections, recently announced that its representatives will present data from its phase 1 study.
The data demonstrates that the company’s H1N1 tablet vaccine provokes T cell responses based on the doses that the patient receives.
The data will be presented at the IDWeek 2015 hosted in San Diego, California. Dr. Peters will make a presentation titled “An Adenovirus Based Influenza Tablet Vaccine Induces Dose Dependent T Cell Responses.” Her presentation is scheduled for Friday, Oct. 9 between 12:30 and 2 p.m. (PDT). It will be located in the San Diego Convention Center in Poster Hall.
Vaxart specializes in developing tablet vaccines using the company’s proprietary oral recombinant vaccine platform. These vaccines are administered through convenient, room temperature, stable tablets. The tablets are able to be shipped and stored without any refrigeration. They are easy to administer to patients, and they also erase any risk of medical waste or needle-stick injury, which are serious concerns with injection vaccines.
These new tablet vaccines could change healthcare for future generations, as the vaccines are now more easily accessible to people who live in developing countries or regions that are difficult to reach with medical supplies.
